1. P04.55 Efficacy of Tumor Treating Fields (TTFields) and aurora B kinase inhibitor. (19th September 2018) Authors: Krex, D; Bartmann, P; Temme, A; Schneiderman, R; Voloshin, T; Giladi, M; Kinzel, A; Kirson, E; Weinberg, U; Palti, Y Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P01.121 Optune treatment does not affect quality of life in treatment of high grade glioma compared to chemo-radiotherapy alone. (19th September 2018) Authors: Onken, J; Goerling, U; Heinrich, M; Guenes, S; Krex, D; Vajkoczy, P; Misch, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P01.121 Optune treatment does not affect quality of life in treatment of high grade glioma compared to chemo-radiotherapy alone. (19th September 2018) Authors: Onken, J; Goerling, U; Heinrich, M; Guenes, S; Krex, D; Vajkoczy, P; Misch, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OS06.5.A Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - the PriCoTTF phase I/II trial. (5th September 2022) Authors: Kebir, S; Lazaridis, L; Schmidt, T; Oster, C; Feldheim, J; Glas, M; Pierscianek, D; Proescholdt, M; Hau, P; Grosu, A; Krex, D; Scheffler, B; Kleinschnitz, C; Pöttgen, C; Stuschke, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P11.21.B Distinct age-related molecular and clinical features inIDH-Wildtype Glioblastoma. (5th September 2022) Authors: Richter, S; Stasik, S; Schackert, G; Thiede, C; Krex, D; Juratli, T A Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P14.64 PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. (9th September 2021) Authors: Kebir, S; Pierscianek, D; Proescholdt, M; Hau, P; Grosu, A; Krex, D; Sure, U; Scheffler, B; Stuschke, M; Glas, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗